Immunotherapy for advanced renal cell cancer.

Keyphrases

• Interferon-α (IFN-α) 100%
• Advanced Renal Cell Carcinoma (aRCC) 100%
• Response Rate 60%
• Randomized Controlled Trial 40%
• Interleukin-2 40%
• Hazard Ratio 40%
• Survival Benefit 40%
• High-dose interleukin-2 40%
• Disease Progression 20%
• Placebo-controlled Study 20%
• Improved Outcomes 20%
• Low Power 20%
• Control Arm 20%
• Treatment Response 20%
• Randomized Controlled Study 20%
• Chemotherapy 20%
• Immunotherapeutics 20%
• Treatment Effect 20%
• Urologic 20%
• Outcome-based 20%
• MEDLINE 20%
• Embase 20%
• Uncontrolled Study 20%
• Complete Response Rate 20%
• Cochrane Library 20%
• Median Survival 20%
• Dose-response Study 20%
• Rate Difference 20%
• Library Databases 20%
• Survival Outcomes 20%
• Intermediate Endpoint 20%
• Average Response 20%
• Modified Schedule 20%
• Systemic Agents 20%
• Dichotomous Outcomes 20%
• Spontaneous Remission 20%
• Differential Survival 20%

Nursing and Health Professions

• Alpha Interferon 100%
• Immunotherapy 100%
• Malignant Neoplasm 100%
• Interleukin 2 100%
• Renal Cell Carcinoma 75%
• Hazard Ratio 50%
• Drug Megadose 50%
• Cochrane Library 25%
• Remission 25%
• Averaging 25%
• Randomization 25%
• Disease Exacerbation 25%
• Treatment Response 25%
• Independent Reviewer 25%
• Placebo-Controlled Study 25%
• Immunomodulating Agent 25%
• Alpha2 Interferon 25%
• Chemotherapy 25%

Medicine and Dentistry

• Cancer Cell 100%
• Arm 100%
• Immunotherapy 100%
• Interferon Alfa 66%
• Interleukin 2 66%
• Clear Cell Renal Cell Carcinoma 50%
• Drug Megadose 33%
• Randomized Controlled Trial 33%
• Hazard Ratio 33%
• Disease Exacerbation 16%
• Placebo-Controlled Study 16%
• Spontaneous Remission 16%
• Treatment Response 16%
• Dose Response 16%
• Independent Reviewer 16%
• Immunomodulating Agent 16%
• Alpha2 Interferon 16%
• Treatment Effect 16%
• Chemotherapy 16%